Aardvark Therapeutics Inc. (AARD)
AARD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$4.04
-9.21% on the day
Market cap
$88.4M
Micro cap
Revenue · 2025
$0
No prior year to compare
Net income · 2025
-$57.6M
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1774857/000119312526119770/0001193125-26-119770-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | AARD on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2025 |
| SEC CIK | 0001774857 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$57.6M |
| Operating income | -$62.7M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $47.1M |
| Total assets | $117.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-04-03 |
| Latest annual report | 10-K | 2026-03-23 |
| Latest quarterly / interim | 10-Q | 2026-08-11 |
| Latest current report | 8-K | 2026-10-08 |
| Latest proxy | DEF 14A | 2026-07-10 |
Source: SEC EDGAR submissions feed, 112 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RLYB | Rallybio Corporation | $16.72 | -0.42% | $88.8M |
| BMEA | Biomea Fusion Inc. | $1.26 | -7.35% | $91.3M |
| RTSN | Retension Pharmaceuticals Inc. | $11.63 | +2.74% | $91.7M |
| CRBP | Corbus Pharmaceuticals Holdings Inc. | $4.78 | -9.30% | $92.5M |
| ANIX | Anixa Biosciences Inc. | $2.67 | -5.99% | $92.8M |
| EQ | Equillium Inc. | $1.32 | -12.00% | $83.7M |
| IMUX | Immunic Inc. | $6.89 | -13.33% | $94.0M |
| OKUR | OnKure Therapeutics Inc. | $2.35 | -3.10% | $95.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier